BOCA RATON, Fla., Feb. 22 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals will announce 2005 fourth quarter and year- end financial results on Thursday, February 23, 2006, after market close. The company will also host a live webcast at 4:30 p.m. ET.
The live webcast can be accessed at http://phx.corporate- ir.net/phoenix.zhtml?p=irol-eventDetails&c=100445&eventID=1219497 or via the Nabi Biopharmaceuticals website at http://www.nabi.com . If you do not have Internet access, the U.S./Canada call-in number is 866-383-8108, conference code 43071086, and the international call-in number is 617-597-5343, conference code 43071086. An audio replay will be available for U.S./Canada callers at 888-286-8010, conference code 95917960, and for international callers at 617-801-6888, conference code 95917960.
An archived version of the webcast will be available at the same Internet address through March 2, 2006. The audio replay will also be available through March 2, 2006. The press release will be available on the company's website at http://www.nabi.com .
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. The company has three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium (for injection)]. Nabi Biopharmaceuticals is focused on developing products which address unmet medical needs and offer commercial opportunities in our core business areas: Gram-positive bacterial infections, hepatitis, kidney disease (nephrology) and nicotine addiction. For a complete list of pipeline products, please go to http://www.nabi.com/pipeline/index.php . The company traces its history to 1967 and is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our website at http://www.nabi.com .
Thomas E. Rathjen Vice President, Investor Relations 561-989-5800 http://www.nabi.com
Audio: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=100445&eventID=1219497Nabi BiopharmaceuticalsCONTACT: Thomas E. Rathjen, Vice President, Investor Relations, NabiBiopharmaceuticals, +1-561-989-5800
